Loading stock data…
Alpha Cognition Inc. (ACOG)
$9.52
After Hours$9.99+0.47 (+4.95%)· Last close Sep 8
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alpha Cognition Inc. Common Stock in the Healthcare sector is trading at $9.52 with a market capitalization of $132M. Wall Street consensus targets $18.00 (5 analysts), implying a +89.1% move over the next 12 months. The stock is currently near its 52-week high of $10.14, remaining 43.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +89.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.53M↑ | $2.79M↓ | $2.84M↑ | $1.66M↓ | $2.93M |
| Gross Profit | $3.26M↑ | $2.54M↑ | $2.21M↑ | $1.12M↓ | $2.09M |
| Operating Income | -$8.10M↓ | -$7.93M↓ | -$5.30M↑ | -$5.74M↓ | -$3.33M |
| Net Income | -$6.48M↑ | -$6.86M↓ | -$1.32M↑ | -$10.49M↓ | -$1.73M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tab...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$132.39M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.76%
Volume
Today's trading volume
85,272
Recent News
Alpha Cognition (ACOG) Stock Fair Value Rises After Zunveyl Analyst Optimism
The fair value price target for Alpha Cognition has shifted from about US$14.67 to US$16.75, which places the stock in a higher valuation range than before. Recent analyst commentary links this move to expectations around Zunveyl, including early launch progress, payer access, and the potential to address tolerability issues seen with existing Alzheimer’s therapies. As you read on, you will see how these factors fit into the evolving Alpha Cognition story and how to track new information as...
Alpha Cognition Inc. Common Stock Q2 2026 Earnings Call Summary
Moby summary of Alpha Cognition Inc. Common Stock's Q2 2026 earnings call
Alpha Cognition (ACOG) Q2 2026 Earnings Call Transcript
ZUNVEYL revenue surged 71% sequentially as repeat prescriber rates hit 76%.
Alpha Cognition Q2 Earnings Call Highlights
Alpha Cognition (NASDAQ:ACOG) reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer’s treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the first quarter, as the company cited growing prescriber adoption and deeper use in long-term care facil
Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates
Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of -2.56% and +41.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?